Page 424 - Read Online

Cerna et al. Nanodrugs in brain tumors

Clinical studies in brain tumors Patient consent
A phase I clinical study of paclitaxel-Angiopep-2 No patient involved.
peptide-drug conjugate that binds to the low-density
lipoprotein receptor-related protein-1 receptor Ethics approval
(GRN1005) has been carried out in patients with This article does not contain any studies with human
recurrent glioma grade 2-4. The clinical data show that participants or animals.
GRN1005 facilitated the penetration of paclitaxel into
tumor tissue. However, interim analysis of the phase REFERENCES
[72]
II trial did not show therapeutic response. [73]
1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A,
Transferrin conjugated with diphteric toxin (Tf-CRM107) Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours
demonstrated in vitro and in vivo toxicity to glioma 2. of the central nervous system. Acta Neuropathol 2007;114:97-109.
Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical
cells and was effective when administrated locally to report: primary brain and central nervous system tumors diagnosed in
xenografts. Using local administration, low toxicity and the United States in 2005-2009. Neuro Oncol 2012;14:1-49.
tumor response were demonstrated in patients with 3. Wilson TA, Karajannis MA, Harter DH. Glioblastoma multiforme:
recurrent high grade brain tumors in phase I and II State of the art and future therapeutics. Surg Neurol Int 2014;5:64.
clinical trials. The response rate was 35% and overall 4. Rivkin M, Kanoff RB. Metastatic brain tumors: current therapeutic
survival of responders was 74 weeks. Unfortunately, options and historical perspective. J Am Osteopath Assoc
[74]
2013;113:418-23.
an early phase III clinical trial using this therapy had 5. Fokas E, Steinbach JP, Rödel C. Biology of brain metastases and novel
to be terminated due to disappointing preliminary targeted therapies: time to translate the research. Biochim Biophys
results. [75] Acta 2013;1835:61-75.
6. Liu C, Zong H. Developmental origins of brain tumors. Curr Opin
In a clinical study of liposomal doxorubicin in patients Neurobiol 2012;22:844-9.
with high-grade gliomas, Fabel et al. found improved 7. Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. Nanotechnology in
[75]
overall survival than in past trials using conventional 8. cancer therapy. J Drug Target 2013;21:904-13.
Bhowmik A, Khan R, Ghosh MK. Blood brain barrier: a challenge for
therapies. Hau et al. demonstrated that pegylated effectual therapy of brain tumors. Biomed Res Int 2015;320941.
[77]
liposomal doxorubicin in patients with recurrent high- 9. Dostalova S, Heger Z, Kudr J, Vaculovicova M, Adam V, Stiborova M,
grade glioma was efficacious and well tolerated. Eckschlager T, Kizek R. Apoferritin: protein nanocarrier for targeted
delivery. In: Naik J, editor. Nano Based Drug Delivery. Zagerb: IAPC
These results presented above suggest that some Publishing; 2015. p. 217-33.
nanodrugs may be efficient in therapy of high grade 10. Ediriwickrema A, Saltzman WM. Nanotherapy for cancer: targeting
brain tumors, a topic of great potential interest for and multifunctionality in the future of cancer therapies. ACS Biomater
Sci Eng 2015;1:64-78.
clinicians. 11. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in
health and disease. Pharmacol Rev 2005;57:173-85.
FUTURE DIRECTIONS AND CONCLUSIONS 12. Bhowmik A, Khan R, Ghosh MK. Blood brain barrier: a challenge for
effectual therapy of brain tumors. Biomed Res Int 2015;2015:320941.
Although the available clinical trial data are limited, 13. Rapoport SI. Modulation of blood-brain barrier permeability. J Drug
Target 1996;3:417-25.
evidence suggests that nanoparticles have potential in 14. Tsuji A, Tamai I. Sodium- and chloride-dependent transport of taurine
diagnosis, operative management and adjuvant therapy at the blood-brain barrier. Adv Exp Med Biol 1996;403:385-91.
for brain tumors. Because the field of nanotechnology 15. Groothuis DR. The blood-brain and blood-tumor barriers: a review of
is young, the long-term health effects of nanoparticles strategies for increasing drug delivery. Neuro Oncol 2000;245-59.
are currently unknown. More study of nanoparticle 16. Clark AJ, Davis ME. Increased brain uptake of targeted nanoparticles
biodistribution, pharmacokinetics, toxicity and role in by adding an acid-cleavable linkage between transferrin and the
therapeutic protocols is warranted if nanoparticles are nanoparticle core. Proc Natl Acad Sci U S A 2015;112:12486-91.
to attain regular clinical use. 17. Patra CR, Bhattacharya R, Mukhopadhyay D, Mukherjee P.
Fabrication of gold nanoparticles for targeted therapy in pancreatic
cancer. Adv Drug Deliv Rev 2010;62:346-61.
Financial support and sponsorship 18. Gu FX, Karnik R, Wang AZ, Alexis F, Levy-Nissenbaum E, Hong S,
Preclinical research of nanodrugs is supported by Langer RS, Farokhzad OC. Targeted nanoparticles for cancer therapy.
GACR (NANOCHEMO 14-8344S) and by the Ministry Nano Today 2007;2:14-21.
of Health of the Czech Republic for conceptual 19. Chomoucka J, Drbohlavova J, Huska D, Adam V, Kizek R, Hubalek J.
development of research organization 00064203 Magnetic nanoparticles and targeted drug delivering. Pharmacol Res
2010;62:144-9.
(University Hospital Motol, Prague, Czech Republic). 20. Adiseshaiah PP, Hall JB, McNeil SE. Nanomaterial standards for
efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed
Conflict of interest Nanobiotechnol 2010;2:99-112.
There are no conflicts of interest. 21. Kanthamneni N, Sharma S, Meenach SA, Billet B, Zhao JC, Bachelder
414 Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ October 31, 2016